// App-Quantinova.ai

PB1572 : PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB VS PLACEBO + LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL): INMIND

Researchers

Presenter

  • Christian Scholz

Principal Investigators

  • Kai Hubel

  • Stefano Luminari

  • Antonio Salar

  • Bjorn Wahlin

  • Ajay Gopal

  • Christophe Bonnet

  • Shankara Paneesha

  • Oliver Manzke

  • Francis Sequy

  • Di Li

  • Laurie Sehn

Medical Centers

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • BC Cancer Centre for Lymphoid Cancer,Vancouver,Canadá

  • Hematology Unit,Azienda USL-IRCCS di Reggio Emilia,Reggio Emilia,Italia

  • Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden

  • Department of Internal Medicine I Oncology and Hematology,University Hospital Cologne,Cologne,Germania

  • Incyte Biosciences International Sàrl,Morges,Schweiz

  • Department of Hematology and Oncology,Vivantes Klinikum Am Urban,Berlin,Deutschland

  • The University of British Columbia, Vancouver, BC, Canada

  • Department of Hematology, Hospital del Mar, Barcelona, Spain

  • Division of Medical Oncology,University of Washington Medicine,Seattle,États-unis

  • Incyte Corporation,Wilmington, DE,Verenigde Staten

  • Clinical Hematology,Centre Hospitalier Universitaire, University of Liège,Liège,Belgien

Locations

  • United Kingdom

  • Canada

  • Italy

  • Sweden

  • Germany

  • Switzerland

  • Spain

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Cardiovascular (CVS)

Disease

  • Congestive heart failure

  • Mucosa-associated lymphoid tissue lymphoma

  • Follicular lymphoma

  • CNS lymphoma

  • Lymphomas

Biomarkers

  • Creatinine

Drug/Treatment

  • Lenalidomide

  • Tafasitamab

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01685008

  • NCT02399085

  • NCT04680052

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved